Molecular predictors of treatment and outcome in colorectal cancer

Current Gastroenterology Reports

Volumn 5, Issue 5, 2003, Pages 399-405

  Iqbal, Syma ^a   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GENE PRODUCT; IRINOTECAN; MOLECULAR MARKER; OXALIPLATIN; PHOSPHORYLASE; PLATINUM DERIVATIVE; THYMIDYLATE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; TUMOR MARKER;

COLORECTAL CANCER; DNA REPAIR; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; INDIVIDUALIZATION; PREDICTION; PROGNOSIS; REVIEW; RISK REDUCTION; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT PLANNING; BLOOD; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PREDICTION AND FORECASTING; RISK FACTOR;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 1542705896     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-003-0053-3     Document Type: Review

References (33)

1. Cancer Facts and Figures. Atlanta, GA: ACS Surveillance Research; 2003.
2. SEER Cancer Statistics Review: 1997-2000. Bethesda, MD: National Institutes of Health; 1993.
3. Saltz LB, Cox JV, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000, 343:905-914.
4. Wolmark N, Rockette H, Fisher B, et al.: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993, 11:1879-1887.
5. Watanabe T, Wu TT, Catalano PJ, et al.: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001, 344:1196-1206.
6. Miyamoto S, Ochiai A, Boku N, et al.: Discrepancies between the gene expression, protein expression, and enzymatic activity of thymidylate synthase and dihydropyrimidine dehydrogenase in human gastrointestinal cancers and adjacent normal mucosa. Int J Oncol 2001, 18:705-713.
7. Berger SH, Jeng C-H, Johnson LF, et al.: Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol Pharmacol 1985, 28:461-467.
8. Peters GJ, van der Wilt CL, van Groeningen CJ, et al.: Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 1994, 12:2035-2042.
9. Johnston PG, Fisher ER, Rockette HE, et al.: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994, 12:2640-2647.
10. Lenz HJ, Danenberg KD, Leichman CG, et al.: p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. Clin Cancer Res 1998, 4:1227-1234.
11. Aschele C, Domizia D, Stefania C, et al.: Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 1999, 17:1760-1770.
12. Johnston PG, Lenz H-J, Leichman CG, et al.: Thymidylate synthase protein and gene expression predicts for response to 5-fluorouracil, leucovorin in patients with colorectal and gastric cancer. Cancer Res 1995, 55:1407-1412.
13. Leichman CG, Lenz HJ, Leichman L, et al.: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997, 15:3223-3229.
14. Metzger R, Danenberg K, Leichman CG, et al.: High basal level gene expression of thymidine phosphorylase (platelet derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 1998, 4:2371-2376.
15. Ishikawa T, Sekiguchi F, Fukase Y, et al.: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998, 58:685-690.
16. Diaso RB, Lu Z: Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J Clin Oncol 1994, 12:2239-2242.
17. Diaso RB, Beavers TL, Carpenter JT: Familial deficiency of DPD: biochemical basis for familial pyrimidinemia severe 5-FU induced toxicity. J Clin Invest 1988, 81:47-51.
18. Lu Z, Zhang R, Diasio RB: DPD activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients and clinical implications in 5-FU chemotherapy. Cancer Res 1993, 53:5433-5438.
19. Danenberg K, Salonga D, Park CG, et al.: DPD and TS gene expressions identify a high percentage of colorectal tumors responding to 5-FU [abstract]. Proc ASCO 1998, 17:992.
20. Uetake H, Ichikawa W, Takechi T, et al.: Relationship between intratumoral dihydropyrimidine dehydrogenase activity and gene expression in human colorectal cancer. Clin Cancer Res 1999, 5:2836-2839.
21. Salonga D, Danenberg M, Metzger R, et al.: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000, 6:1322-1327.
22. Horie N, Aiba H, Oguro K, et al.: Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995, 20:191-197.
23. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al.: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001, 1:65-70.
24. Kawakami K, Omura K, Kanehira E, et al.: Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 1999, 19:3249-3252.
25. Elsaleh H, Fabianne G, Joseph D, et al.: Thymidylate synthase genotype and survival benefit from chemotherapy in patients with colorectal cancer [abstract]. Proc ASCO 2001, 20:493.
26. Park DJ, Stoehlmacher J, Zhang W, et al.: Thymidylate synthase gene polymorphism predicts response to capecitabine chemotherapy in advanced colorectal cancer. Int J Colorectal Dis 2001, 17:46-49.
27. Van Houten B: Nucleotide excision repair in Escherichia coli. Microbiol Rev 1990, 54:18-51.
28. Hoeijmakers JH: Nucleotide excision repair. II: From yeast to mammals. Trends Genet 1993, 9:211-217.
29. de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938-2947.
30. de Gramont A, Bensmaine MA, Louvet C, et al.: Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999, 17:3560-3568.
31. Goldberg RM, Morton RF, Sargent DJ, et al.: N9741: oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC): initial toxicity and response data from a GI Intergroup study [abstract]. Proc ASCO 2002, 21:511.
32. Shirota Y, Stoehlmacher J, Brabender J, et al.: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001, 19:4298-4304.
33. Park D, Stoehlmacher J, Zhang W, et al.: ERCC1 polymorphism associated with ERCC1 mRNA expression [abstract]. Proc AACR 2002, 43:1591.